loading...| Preferred Name |
Rifaximin |
|
| Synonyms |
|
|
| Definitions |
An orally administered, semi-synthetic, nonsystemic antibiotic derived from rifamycin SV with antibacterial activity. Rifaximin binds to the beta-subunit of bacterial DNA-dependent RNA polymerase, inhibiting bacterial RNA synthesis and bacterial cell growth. As rifaximin is not well absorbed, its antibacterial activity is largely localized to the gastrointestinal tract. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C61926 |
|
| CAS_Registry |
80621-81-4 |
|
| Chemical_Formula |
C43H51N3O11 |
|
| code |
C61926 |
|
| Contributing_Source |
CTRP FDA |
|
| definition |
An orally administered, semi-synthetic, nonsystemic antibiotic derived from rifamycin SV with antibacterial activity. Rifaximin binds to the beta-subunit of bacterial DNA-dependent RNA polymerase, inhibiting bacterial RNA synthesis and bacterial cell growth. As rifaximin is not well absorbed, its antibacterial activity is largely localized to the gastrointestinal tract. |
|
| Display_Name |
Rifaximin |
|
| FDA_UNII_Code |
L36O5T016N |
|
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C176424 |
|
| label |
Rifaximin |
|
| Legacy Concept Name |
Rifaximin |
|
| NCI_Drug_Dictionary_ID |
654589 |
|
| PDQ_Closed_Trial_Search_ID |
654589 |
|
| PDQ_Open_Trial_Search_ID |
654589 |
|
| Preferred_Name |
Rifaximin |
|
| prefixIRI |
NCIT:C61926 |
|
| prefLabel |
Rifaximin |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C0073374 |
|
| subClassOf |